Knee Hyaluronic Acid Injections Market Report 2026

The knee hyaluronic acid injections market size has grown strongly in recent years. It will grow from $3.17 billion in 2025 to $3.37 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising prevalence of osteoarthritis, increasing geriatric population, growing adoption of viscosupplementation therapies, expansion of hospital-based orthopedic treatments, limited historical surgical alternatives.

The knee hyaluronic acid injections market size is expected to see strong growth in the next few years. It will grow to $4.35 billion by 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in hyaluronic acid formulation technologies, increasing demand for minimally invasive joint treatments, rising healthcare expenditure on orthopedic care, expansion of outpatient and ambulatory surgical infrastructure, growing focus on regenerative and biological therapies. Major trends in the forecast period include rising adoption of single-injection viscosupplementation for osteoarthritis, increasing preference for minimally invasive orthopedic therapies, growing geriatric population driving osteoarthritis treatment demand, expansion of outpatient orthopedic and ambulatory care settings, increasing clinical research on hyaluronic acid molecular weight efficacy.

The increasing prevalence of obesity is expected to propel the growth of the knee hyaluronic acid injections market going forward. Obesity refers to a medical condition characterized by excessive accumulation of body fat that poses a risk to health, typically assessed using body mass index (BMI). The rising incidence of obesity is contributing to growth due to sedentary lifestyles and declining physical activity levels, which are supporting excessive weight gain and related health complications. Knee hyaluronic acid injections support the management of osteoarthritis symptoms in obese patients by restoring synovial joint lubrication, reducing inflammation, and improving mobility. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, between 2023 and 2024, an estimated 64.5% of adults aged 18 years and above in England were classified as overweight or obese, representing a slight increase from 64% recorded in 2022-2023. Therefore, the rising incidence of obesity is driving the growth of the knee hyaluronic acid injections market.

The increasing prevalence of knee osteoarthritis (OA) is anticipated to support the growth of the knee hyaluronic acid injections market in the coming years. Knee osteoarthritis is a degenerative condition in which the cartilage within the knee joint gradually deteriorates, resulting in pain, stiffness, and limited movement. Factors such as aging populations, higher obesity rates, sedentary behavior, and a growing number of joint-related injuries are contributing to the rising occurrence of this condition. Knee hyaluronic acid injections assist in managing osteoarthritis symptoms by enhancing joint lubrication, alleviating pain and inflammation, and improving mobility and overall knee function. According to the World Health Organization, around 365 million people worldwide were affected by knee osteoarthritis in 2023, with cases continuing to increase due to aging demographics and rising obesity levels, as reported in August 2024. Consequently, the growing incidence of knee osteoarthritis is driving demand for knee hyaluronic acid injections.

Leading companies operating in the knee hyaluronic acid injections market are focusing on developing advanced therapies such as single-injection HA knee treatments to restore synovial fluid viscosity, reduce pain, and improve joint function with one intra-articular administration instead of multiple injections. Single-injection HA knee treatment refers to a medical procedure in which a single dose of hyaluronic acid (HA) is injected into the knee joint to relieve pain and improve mobility, typically in patients with osteoarthritis. For example, in July 2024, LG Chem, a South Korea-based life sciences and pharmaceutical company, introduced Synovian (branded in China as Hyruan ONE), a cross-linked hyaluronic acid injection for knee osteoarthritis in the Chinese market that delivers therapeutic benefits comparable to multi-injection regimens, simplifies treatment to a single visit, and demonstrated safety and efficacy in Phase-3 clinical trials among Chinese patients. Synovian’s single-dose convenience, cross-linked HA formulation for longer intra-articular residence, and inclusion on China’s National Reimbursement Drug List support broader adoption and improved patient compliance, although physician training and insurance uptake vary across regions.

Major companies operating in the knee hyaluronic acid injections market are Johnson & Johnson, Sanofi S. A., Teva Pharmaceutical Industries Ltd., Smith & Nephew plc, Chugai Pharmaceutical Co. Ltd., Zimmer Biomet Holdings Inc., Bioventus Inc., Fidia Farmaceutici S. p. A., Ferring Pharmaceuticals A/S, IBSA Institut Biochimique SA, Anika Therapeutics Inc., Lifecore Biomedical LLC, TRB Chemedica International S. A., Seikagaku Corporation, Hangzhou Singclean Medical Products Co. Ltd., Virchow Biotech Private Limited, OrthogenRx Inc., Shanghai Haohai Biological Technology Co. Ltd., Allergan plc, Shandong Freda Biochem Co. Ltd.

North America was the largest region in the knee hyaluronic acid injections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the knee hyaluronic acid injections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the knee hyaluronic acid injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The knee hyaluronic acid injections market consists of sales of viscosupplementation injections, single and multi-injection formulations, prefilled syringes, and combination therapeutic products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.